Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Enavogliflozin, Metformin, and Glimepiride in Healthy Adults
NCT06644404Phase 1Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State for DWP16001, Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State for DWP16001 and 4 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06644404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644404.